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haemodynamic parameters in two study groups: children
presenting with metabolic acidosis (base deﬁcit > 8) and
children without acidosis. Acidotic patients received ﬂuid
resuscitation with either Dextran 70 or Hetastarch at admis-
sion.
Results: Several markers of haemodynamic compromise
were noted on admission including severe tachycardia,
low stroke volume index (SVI) and high inferior vena
cava collapsibility index (IVCCI) that improved with subse-
quent readings (ﬁg 1). Overall, cardiac function assessed
by ejection fraction (63.1%± 5.2 vs. 71.9%± 2.8 P=<0.001)
and left myocardial performance index (LMPI) (0.32± 0.16
vs. 0.25± 0.08 P = 0.03) was mildly abnormal on admis-
sion compared to discharge. Acidotic patients had worse
haemodynamic indicators, with signiﬁcantly higher IVCCI
on day 0 than non-acidotic patients (52.1± 21 .9 vs.
37.7± 15.4 P = 0.03); plus lower SVIs and worse cardiac func-
tion with higher LMPI (0.38± 0.18 vs. 0.26± 0.11 P = 0.05).
SVI increased post ﬁrst ﬂuid bolus in 80% of acidotic chil-
dren, from an average of 36.7ml/m2 (95% CI: 30.9- 42.5) to
41.5ml/m2 (95%CI: 37.19- 45.8, P = 0.007).
Inferior Vena Cava collapsibility Index in severe malaria
by acidosis over time
Conclusion: Children with severe malaria have evidence
of intravascular volume depletion and associated mild car-
diac dysfunction which are more marked in those with
metabolic acidosis. By optimizing cardiac output, this might
aid microvascular ﬂow and tissue perfusion with the aim
of impacting on the metabolic derangement and associated
high mortality in these children.
doi:10.1016/j.ijid.2010.02.1736
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ransfusion-associated Babesia infections: Reports
eceived by the FDA 1997 to 2008
. Gubernot ∗, K.C. Lee, G.B. Conley, L.G. Holness, S.
’Callaghan, S. Cannon, E. Cowan, H. Nakhasi, R.P. Wise
Food and Drug Administration, Rockville, MD, USA
Background: Babesiosis is a known transfusion-
ransmitted disease risk and there is no FDA-licensed
est for donor screening. Approximately 80 transfusion-
ransmitted cases have been reported 1979 through 2008.
his research evaluated the Babesia-related transfusion
vents reported to the Food and Drug Administration (FDA)
ith particular focus on numbers and characteristics of
ransfusion-related babesiosis fatality reports.
Methods: Data were collected from FDA’s Blood Col-
ection and Transfusion Fatality Reporting and Biological
roduct Deviation Reports (BPDRs) surveillance systems.
Results: From 2005 through 2008, the FDA received 10
ransfusion-related babesiosis fatality reports after only one
rior report in 1998. Recipients presented with symptoms
.5 to 9 weeks after transfusion of implicated red blood
ell units. In recent years, FDA has also seen an increase
n Babesia-related BPDRs involving donors with post dona-
ion illness and reports of potential transfusion-transmitted
isease. Most reports submitted to the FDA implicate B.
icroti.
Conclusion: The reports received by the FDA indicate
abesia infection may be a rare but increasing risk to the
lood supply. Without a licensed screening test to pre-
ent these transmissions, enhanced clinician awareness of
he possibility of babesiosis in febrile, recent transfusion
ecipients may facilitate prompt diagnosis, improved prog-
osis, and more timely investigations to interdict infected
nits. Prompt reporting of babesiosis donor and transfusion-
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sector must be addressed. In Sierra Leone, a speciﬁc anti-
malarial importation policy could allow for uniformity and
improve adherence to nationally recommended standards.
doi:10.1016/j.ijid.2010.02.1739114 14
elated events assists the FDA in assessing the scope of this
isk and developing appropriate public health control mea-
ures.
Disclaimer: The ﬁndings and conclusions in this abstract
ave not been formally disseminated by the Food and Drug
dministration and should not be construed to represent any
gency determination or policy.
oi:10.1016/j.ijid.2010.02.1737
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linical and epidemiological study of patients withmalaria
reated at the hospital central de Las Fuerzas Armadas in
ominican Republic
. Rodriguez-Taveras, L.C. Socias, C. Blanco, J.R. Reyes ∗,
.M. Puello
Hospital Central de Las Fuerzas Armadas, Santo Domingo,
ominican Republic
Background: As a tropical country, Dominican Republic
s a malaria endemic area and although it has reduced its
ncidence, continues to be in the differential diagnosis of
ebrile illnesses.
Methods: This is a retrospective study to assess the
pidemiological and clinical characteristics of patients diag-
osed with Malaria admitted from January 2008 to November
009, at the hospital, a tertiary-care center, and regional
eference, that serves to the military population, relatives
f these and the civilian population as social action. Inclu-
ion criteria were suspected diagnosis of Malaria at the time
f admission and conﬁrmed by the presence of asexual forms
n thin blood smears or thick made at the time of initial
valuation.
Results: Of 93 febrile patients admitted with suspected
alaria, this diagnosis was conﬁrmed in 13 (13.9%), 11
84.6%) were men. The mean age found was 32 Years (range
5-62). While 46.1% were found within Santo Domingo and
istrito Nacional, the distribution by region was: South
7.7%), North (7.7%), the border region (38.5%). All were
ymptomatic at diagnosis. The typical clinical presentation
bserved in most cases: fever (98.4%), headache (85.6%),
hills (46.6%), myalgia (34.5%) and jaundice (10.9%). All
ere managed within the hospital, required standard of
his military institution. All cases were autochthonous and
. falciparum were the only parasite found in all the
atients, responding satisfactory to chloroquine and pri-
aquine treatment. Death occurred in 1 (7.7%). The average
ime between the start of clinical setting and the diagnosis
as 6.5 days for patients who were transfer from other parts
f the country and 2.8 days (p < 0.05) for those who came
eeking medical care directly in the hospital.
Conclusion: Attention should be given to febrile patients,
nd test to investigate malaria must be included as a rou-
ine, regardless of the provenance, but especially those
iving in the border region with Haiti, the interval between
he clinical setting and the diagnosis has a prognosis value.
he P. falciparum is the unique species prevalent in Domini-
an Republic, and chloroquine and primaquine continues to
e therapeutic option of choice.
oi:10.1016/j.ijid.2010.02.1738ternational Congress on Infectious Diseases (ICID) Abstracts
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rtemisinin combination therapies: Public and private
arket and policy surveys in Burundi and Sierra Leone
. Amuasi 1,∗, Y. Karikari 1, I. Boakye1, S. Blay1, L.
sabiyumva2, A. Jambai3, G. Diap4
Komfo Anokye Teaching Hospital, KUMASI, Ghana
National Malaria Control Program, BUJUMBURA, Burundi
Ministry of Health, FREETOWN, Sierra leone
Drugs for Neglected Diseases Initiative, Geneva, Switzer-
and
Background: Access to Artemisinin-based Combination
herapies (ACTs) is still limited in Africa, even though ACTs
re recommended by the WHO since 2002. In order to bet-
er understand the situation where access has traditionally
een limited, policy analyses and market surveys on anti-
alarial availability and accessibility have been conducted
n selected countries where the ACT, artesunate and amodi-
quine (AS + AQ), has been adopted as ﬁrst line.
Methods: The analyses described here were conducted
n the public and private sectors of Burundi and Sierra
eone using internationally standardized methodologies.
ata were obtained by reviewing publications; interviewing
elevant health stakeholders; and visiting hospitals, health
entres, pharmacies, and drug sale outlets.
Results: Patients are not accessing ACTs due to systemic
arriers varying between countries. In Burundi, quinine was
he most common over-the-counter antimalarial found in all
ectors despite not being ﬁrst line and being more expensive
han ACTs. Chloroquine (CQ), which has been banned from
mportation, was not found. Public sector cost of AS + AQ
0.16 USD) was found to be 1/5 the cost in the private sector
p = 0.00021). In Sierra Leone, no antimalarial importation
olicy exists, the average cost of AS + AQ was approximately
hree times the cost of CQ. Although antimalarials like
S + AQ are not expected to be sold in the public sector,
S + AQ was found in three public sector outlets at a higher
ost (1.88 USD) than either the mission/NGO cost or the
rivate-sector cost (p < 0.0001).
Conclusion: Having on-the-ground data best informs the
alaria community - including the partnership who made
he ﬁxed-dose AS/AQ available in 2007 - on how to overcome
ccess barriers to the widespread adoption and proper use of
CTs. In Burundi, the paucity and cost of ACTs in the private
